An Open-label, Multi-center Clinical Trial of Eculizumab in Adult Patients With Atypical Hemolytic-uremic Syndrome

Study Identifier:
C10-004
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete

Study Details

Medical Condition
  • Unmapped
Study Drug
  • Drug: Eculizumab
Date
Jul 2010 - Oct 2013
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years
Requirements Information
Sex
Female & Male
Age
18+ years

Study Details

Medical Condition
  • Unmapped
Study Drug
  • Drug: Eculizumab
Date
Jul 2010 - Oct 2013
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years years
Requirements Information

Protocol Summary

The record Primary purpose is to assess the efficacy of eculizumab in adult patients with Atypical Hemolytic- Uremic Syndrome (aHUS) to control Thrombotic Microangiopathy (TMA) as characterized by thrombocytopenia, hemolysis and renal impairment.

Trial Locations

Location
Status
Location
Burlington, Massachusetts, United States, 01805
Status
N/A
Location
Hackensack, New Jersey, United States, 07601
Status
N/A
Location
New York, New York, United States, 10032
Status
N/A
Location
Columbus, Ohio, United States, 43210
Status
N/A
Location
Houston, Texas, United States, 77030
Status
N/A
Location
Liège, Belgium, 4020
Status
N/A